Benefits of Mammography Outweigh Harms In Women with Increased Risk, Starting at Age 40
ASCO Publishes Guidelines For Dosing Chemotherapy Correctly in Obese Patients
Phase III Regorafenib Trial Meets Endpoint Improving Progression-Free Survival
Researchers Link Cancer Risk And DMPA Birth Control Use
Breast-Conserving Procedures Lead To Frequent Follow-up Care
False-Positive Mammograms Can Indicate Higher Cancer Risk
Proposed Surveillance Model Aims To Reduce Post-Treatment Pain
Adding Avastin Did Not Improve Standard Chemotherapy Regimen
Ibrutinib Demonstrates Responses In Large B-Cell Lymphomas
Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial
Perifosine Fails Primary Endpoint, Zentaris CEO Explores Options
Translplants Not Best Choice in Subset of ALL Patients
PET Response Can Predict Increased Survival In Patients
Cancer Incidence Rates Climb In HIV-Positive Female Populations
Technology Isolates and Recovers Circulating Liver Tumor Cells
Survey Shows That One-Third Of Patients Are Undertreated
Trials Approved by NCI CTEP For the Month of April
FDA Approves Votrient For Soft Tissue Sarcomas
Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - CBER Director Vinay Prasad dared to “say no to drugs”
- J. Craig Venter’s work was foundational to cancer advancement of the past 25 years
- Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)
